Warren, R. B., Reich, K., Simpson, E. L., Langley, R., Costanzo, A., Saeki, H., Almgren, P., Vacko, E., Gooderham, M., Deleuran, M., Francisco Silvestre, J., Weidinger, S., & Blauvelt, A. (2022). 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, 6(6), s78. https://doi.org/10.25251/skin.6.supp.78